Chiltern Appoints Jane Turner as Late Phase Director ...( LONDON Feb. 27 /- Chiltern a leading ...),Health

LONDON, Feb. 27 /PRNewswire/ -- Chiltern a leading global clinical research organization announced today that it has appointed Ms. Jane Turner to the post of Director, Late Phase, Europe.

Ms. Turner brings over 24 years of experience to her new position in Chiltern's global Late Phase Organization. Ms. Turner previously held executive positions in both CRO and Pharmaceutical companies, enabling her to acquire considerable knowledge of the operational side of management in both industries. In her most recent position, Jane worked on the management of Late Phase studies with focus on a European setting. Jane's operational base will be Chiltern's global headquarters in Slough, United Kingdom. Jane received a B.Pharm from the University of Nottingham and a Diploma in Clinical Science from the University of Wales.

"I am pleased that Jane chose to bring her expertise and experience to Chiltern," said Steve Albrecht, Chiltern's Senior Director, Late Phase (global). "Our global Late Phase Team has grown significantly over the past few years and Jane's extensive business and operational experience will help us bring innovative and high quality solutions to exceed our sponsors varied Late Phase needs," Steve added.

"I am delighted to join Steve and the global Late Phase group at Chiltern," Jane Turner stated. "There is an increasing demand from both the regulatory authorities and the public for Late Phase studies especially in the domain of drug safety. These requests can negatively affect our sponsors with added costs and time delays; therefore it is imperative that CROs continue to look for innovative solutions while preserving the integrity of the data and the safety of the subjects."

"Jane adds significant strength to our global Late Phase Team," commented James Esinhart, Executive Vice President, Biometrics & Late Phase. "We are experiencing increased demand for Chiltern's Late Phase servic
'/>"/>